Skandinaviska Enskilda Banken (SEB)
RVNC

Skandinaviska Enskilda Banken (SEB)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,041
Closed -$190K – 902
2024
Q4 		$190K Sell
62,041
-84,796
-58% -$369K ﹤0.01% 748
2024
Q3 		$763K Buy
+146,837
New +$730K ﹤0.01% 691

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RVNC Position: Q1 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 62,041 shares — an estimated $190K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $763K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 62,041 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $190K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Revance Therapeutics, Inc. position peaked at $763K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2025, filed 7 May 2025.